Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar
Heba N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 214
Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
Stijn P. Andeweg, Brechje de Gier, Dirk Eggink, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 118
Role of COVID-19 Vaccines in SARS-CoV-2 Variants
Zhou Zhou, Yimiao Zhu, Ming Chu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 74
The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2
Jeffrey P. Townsend, Hayley B. Hassler, Pratha Sah, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 31
Open Access | Times Cited: 69
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada
Sara Carazo, Danuta M. Skowronski, Marc Brisson, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2236670-e2236670
Open Access | Times Cited: 45
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
Jonas Björk, Carl Bonander, Mahnaz Moghaddassi, et al.
Eurosurveillance (2022) Vol. 27, Iss. 18
Open Access | Times Cited: 41
Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance
Lirong Cao, Jingzhi Lou, See Yeung Chan, et al.
Nature Medicine (2022) Vol. 28, Iss. 8, pp. 1715-1722
Open Access | Times Cited: 39
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 10
Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers
Fotinie Ntziora, Evangelia Georgia Kostaki, Αmalia Karapanou, et al.
Vaccine (2022) Vol. 40, Iss. 50, pp. 7195-7200
Open Access | Times Cited: 23
COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups
Sherrie L. Kelly, Epke A. Le Rutte, Maximilian Richter, et al.
Infectious Diseases and Therapy (2022) Vol. 11, Iss. 5, pp. 2045-2061
Open Access | Times Cited: 22
Competition of SARS-CoV-2 variants on the pandemic transmission dynamics
Jiaqi Chen, Changgui Gu, Zhongyuan Ruan, et al.
Chaos Solitons & Fractals (2023) Vol. 169, pp. 113193-113193
Open Access | Times Cited: 14
Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination
Sara Carazo, Danuta M. Skowronski, Marc Brisson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 19
Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
Stijn P. Andeweg, Brechje de Gier, Dirk Eggink, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 15
Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
Elias Tayar, Sami Abdeen, Muna Abed Alah, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 14
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination
Sharon Walmsley, Majid Nabipoor, Freda Qi, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 564-564
Open Access | Times Cited: 2
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
Edwards Pradenas, Sílvia Marfil, Víctor Urrea, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106457-106457
Open Access | Times Cited: 7
Protection against Omicron conferred by mRNA primary vaccine series, boosters, and prior infection
Elizabeth T. Chin, David Leidner, Lauren Lamson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
Ilya Kister, Ryan Curtin, Jinglan Pei, et al.
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 10, pp. 1643-1659
Open Access | Times Cited: 11
Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years
Christine Durier, Läétitia Ninove, M. Lefèbvre, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
Sharon Walmsley, Majid Nabipoor, Leif E. Lovblom, et al.
Vaccines (2023) Vol. 12, Iss. 1, pp. 36-36
Open Access | Times Cited: 4
Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada
Shishi Wu, Yanhong Li, Stefan Baral, et al.
PLoS ONE (2024) Vol. 19, Iss. 2, pp. e0299304-e0299304
Open Access | Times Cited: 1
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha (B.1.1.7), Delta (B.1.617.2) or Omicron (B.1.1.529) dominance: A Danish nationwide study
Katrine Finderup Nielsen, Ida Rask Moustsen-Helms, Astrid Blicher Schelde, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 7
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar
Ahmed Zaqout, Muna Almaslamani, Hiam Chemaitelly, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies
Jingxin Li, Zhuopei Li, Yawen Zhu, et al.
Zoonoses (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 5
‘Imperfect but useful’: pandemic response in the Global South can benefit from greater use of mathematical modelling
Sandip Mandal, Kanchan Parchani, Nimalan Arinaminpathy, et al.
BMJ Global Health (2022) Vol. 7, Iss. 5, pp. e008710-e008710
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top